Researchers report that rentosertib, an AI-discovered TNIK inhibitor, showed promising safety and potential to improve lung ...

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

UBS analyst Eliana Merle reaffirmed a Buy rating and a $582 price target for Vertex Pharmaceuticals, praising the adoption of ...

Five Indian-origin women and an Indian woman have been named in Fortune’s 2025 Most Powerful Women list. The list is topped ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the ...

Reshma Kewalramani, Bela Bajaria, Revathi Advaithi and Meena Lakdawala Flynn among women at the top of the global business ...

Princeton University awarded honorary degrees to Omar M. Yaghi, Daniel Chee Tsui, Nancy Weiss Malkiel, Joshua ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Pharmaceuticals, a biotech giant best known for its cystic fibrosis drugs, took a stumble after missing Q1 2025 ...

today announced that the first patient has been dosed with lead drug candidate RLS-1496 in the company’s single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial.

One of the first and most promising uses scientists envision for the rapidly evolving technology of quantum computing is a new approach to drug development. A quantum computer could, in theory ...